Cyclo Therapeutics Inc (CYTH)
0.7216
-0.03
(-3.53%)
USD |
NASDAQ |
Nov 01, 16:00
0.7228
0.00 (0.00%)
After-Hours: 20:00
Cyclo Therapeutics Enterprise Value: 22.30M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 22.30M |
| October 31, 2024 | 23.05M |
| October 30, 2024 | 22.28M |
| October 29, 2024 | 23.11M |
| October 28, 2024 | 22.39M |
| October 25, 2024 | 22.97M |
| October 24, 2024 | 23.89M |
| October 23, 2024 | 23.11M |
| October 22, 2024 | 23.74M |
| October 21, 2024 | 24.83M |
| October 18, 2024 | 23.80M |
| October 17, 2024 | 24.11M |
| October 16, 2024 | 24.26M |
| October 15, 2024 | 23.11M |
| October 14, 2024 | 22.91M |
| October 11, 2024 | 23.80M |
| October 10, 2024 | 23.69M |
| October 09, 2024 | 22.97M |
| October 08, 2024 | 22.76M |
| October 07, 2024 | 23.11M |
| October 04, 2024 | 22.86M |
| October 03, 2024 | 21.98M |
| October 02, 2024 | 22.57M |
| October 01, 2024 | 23.69M |
| September 30, 2024 | 24.23M |
| Date | Value |
|---|---|
| September 27, 2024 | 22.25M |
| September 26, 2024 | 21.68M |
| September 25, 2024 | 21.30M |
| September 24, 2024 | 20.82M |
| September 23, 2024 | 21.59M |
| September 20, 2024 | 21.96M |
| September 19, 2024 | 21.24M |
| September 18, 2024 | 20.27M |
| September 17, 2024 | 20.24M |
| September 16, 2024 | 20.01M |
| September 13, 2024 | 20.15M |
| September 12, 2024 | 19.95M |
| September 11, 2024 | 20.53M |
| September 10, 2024 | 20.53M |
| September 09, 2024 | 21.13M |
| September 06, 2024 | 21.10M |
| September 05, 2024 | 21.16M |
| September 04, 2024 | 21.98M |
| September 03, 2024 | 22.16M |
| August 30, 2024 | 23.05M |
| August 29, 2024 | 23.68M |
| August 28, 2024 | 24.82M |
| August 27, 2024 | 24.40M |
| August 26, 2024 | 25.34M |
| August 23, 2024 | 23.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.768M
Minimum
Nov 22 2022
66.35M
Maximum
Mar 17 2021
23.58M
Average
22.21M
Median
Oct 30 2020
Enterprise Value Benchmarks
| Stryker Corp | 150.76B |
| Biogen Inc | 29.92B |
| Pfizer Inc | 221.03B |
| Pacira BioSciences Inc | 949.40M |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.981M |
| Revenue (Quarterly) | 0.1231M |
| Total Expenses (Quarterly) | 5.759M |
| EPS Diluted (Quarterly) | -0.21 |
| Gross Profit Margin (Quarterly) | 89.13% |
| Profit Margin (Quarterly) | -4.86K% |
| Earnings Yield | -122.0% |
| Normalized Earnings Yield | -122.07 |